GlassScriptPhysician profile
Gary R Alexander
NPI 1811967797
$2,660.63
in general payments reported to CMS, 2019-2025
34 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $577 · 2023: $458 · 2024: $310 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.44 | 2021-2025 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $285.99 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $254.21 | 2021-2024 | Veozah |
| Pfizer INC. | $219.45 | 2021-2025 | |
| Lilly USA, LLC | $214.28 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $149.38 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.17 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.45 | 2021-2025 | Jardiance, Synjardy |
| Abbvie INC. | $98.09 | 2021-2025 | |
| Dexcom, INC. | $91.60 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $78.40 | 2021-2025 | Minimed 780g |
| Amarin Pharma, INC. | $68.77 | 2021 | |
| Sumitomo Pharma America, INC. | $63.23 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $54.54 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $54.21 | 2022-2025 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $51.20 | 2022 | |
| Corcept Therapeutics | $44.91 | 2022 | |
| Glaxosmithkline, LLC. | $40.14 | 2025 | Shingrix, Arexvy |
| Avanir Pharmaceuticals, INC. | $35.11 | 2021 | |
| Smith+Nephew, INC. | $27.58 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $27.07 | 2021 | |
| Noven Therapeutics, LLC | $24.72 | 2025 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $23.31 | 2022 | |
| Daiichi Sankyo INC. | $19.85 | 2022 | |
| Abbott Laboratories | $17.31 | 2025 | Eterna |
| Merck Sharp & Dohme LLC | $17.08 | 2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2022 | |
| Scilex Pharmaceuticals INC. | $16.93 | 2022 | |
| Axsome Therapeutics, INC. | $16.75 | 2025 | Symbravo |
| Boston Scientific Corporation | $16.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2022 | |
| Clarus Therapeutics INC. | $12.30 | 2021 | |
| Mylan Specialty L.P. | $11.59 | 2021 | |
| Genentech USA, INC. | $9.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.